Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Factor Therapeutics

DB:1TT
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1TT
DB
A$3M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Factor Therapeutics Limited operates as a clinical stage biotechnology company. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
  • Factor Therapeutics has significant price volatility in the past 3 months.
1TT Share Price and Events
7 Day Returns
0%
DB:1TT
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-50%
DB:1TT
-13.2%
DE Biotechs
-20.9%
DE Market
1TT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Factor Therapeutics (1TT) 0% 0% -50% -50% -96.8% -98%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 1TT underperformed the Biotechs industry which returned -13.2% over the past year.
  • 1TT underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
1TT
Industry
5yr Volatility vs Market

1TT Value

 Is Factor Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Factor Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Factor Therapeutics.

DB:1TT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1TT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 30%) (0%))
1.126
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.126 * 5.44%)
5.73%

Discounted Cash Flow Calculation for DB:1TT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Factor Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:1TT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 5.73%)
2020 0.03 Est @ 43.89% 0.03
2021 0.04 Est @ 30.61% 0.03
2022 0.04 Est @ 21.31% 0.04
2023 0.05 Est @ 14.8% 0.04
2024 0.06 Est @ 10.24% 0.04
2025 0.06 Est @ 7.05% 0.04
2026 0.06 Est @ 4.82% 0.04
2027 0.06 Est @ 3.26% 0.04
2028 0.07 Est @ 2.16% 0.04
2029 0.07 Est @ 1.4% 0.04
Present value of next 10 years cash flows A$0.00
DB:1TT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= A$0.07 × (1 + -0.39%) ÷ (5.73% – -0.39%)
A$1.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$1.09 ÷ (1 + 5.73%)10
A$0.62
DB:1TT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$0.00 + A$0.62
A$0.62
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$0.62 / 1,042.84
A$0
DB:1TT Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1TT represents 0.5x of ASX:FTT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.5x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (AUD) x Listing Adjustment Factor
= A$ 0.00 x 0.5
€0.00
Value per share (EUR) From above. €0.00
Current discount Discount to share price of €0.00
= -1 x (€0.00 - €0.00) / €0.00
-235.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Factor Therapeutics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Factor Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Factor Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1TT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in AUD A$0.00
ASX:FTT Share Price ** ASX (2020-04-03) in AUD A$0
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Factor Therapeutics.

DB:1TT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:FTT Share Price ÷ EPS (both in AUD)

= 0 ÷ 0.00

1.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Factor Therapeutics is good value based on earnings compared to the Europe Biotechs industry average.
  • Factor Therapeutics is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Factor Therapeutics's expected growth come at a high price?
Raw Data
DB:1TT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Factor Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Factor Therapeutics's assets?
Raw Data
DB:1TT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in AUD A$0.00
ASX:FTT Share Price * ASX (2020-04-03) in AUD A$0
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:1TT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:FTT Share Price ÷ Book Value per Share (both in AUD)

= 0 ÷ 0.00

0.72x

* Primary Listing of Factor Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Factor Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Factor Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Factor Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1TT Future Performance

 How is Factor Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Factor Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Factor Therapeutics expected to grow at an attractive rate?
  • Unable to compare Factor Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Factor Therapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Factor Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1TT Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1TT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1TT Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:1TT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 0 2
2019-09-30 2 -2 -1
2019-06-30 2 -4 -4
2019-03-31 1 -6 -8
2018-12-31 0 -8 -11
2018-09-30 1 -6 -9
2018-06-30 2 -4 -8
2018-03-31 2 -5 -7
2017-12-31 3 -6 -7
2017-06-30 4 -7 -6
2017-03-31 3 -6 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Factor Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Factor Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1TT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Factor Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1TT Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:1TT Past Financials Data
Date (Data in AUD Millions) EPS *
2019-12-31 0.00
2019-09-30 0.00
2019-06-30 0.00
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-06-30 -0.01
2017-03-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Factor Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Factor Therapeutics is trading at Factor Therapeutics'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Factor Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Factor Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Factor Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Factor Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1TT Past Performance

  How has Factor Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Factor Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Factor Therapeutics has delivered over 20% year on year earnings growth in the past 5 years.
  • Factor Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Factor Therapeutics has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Factor Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Factor Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1TT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2.49 1.67 0.50
2019-09-30 2.44 -1.25 1.08 0.19
2019-06-30 2.38 -4.17 1.65 0.38
2019-03-31 1.22 -7.56 2.26 0.58
2018-12-31 0.05 -10.96 2.87 0.78
2018-09-30 0.87 -9.33 3.02 0.69
2018-06-30 1.68 -7.69 3.17 0.60
2018-03-31 2.47 -7.42 3.09 0.57
2017-12-31 3.25 -7.14 3.00 0.54
2017-06-30 3.93 -5.59 2.68 0.44
2017-03-31 3.20 -4.51 2.54 0.30
2016-12-31 2.48 -3.42 2.39 0.17
2016-09-30 1.45 -7.52 2.25 0.17
2016-06-30 0.43 -11.61 2.11 0.16
2016-03-31 0.38 -13.69 2.55 0.27
2015-12-31 0.32 -15.77 2.99 0.38
2015-09-30 0.34 -13.49 3.68 0.49
2015-06-30 0.36 -11.22 4.37 0.60
2015-03-31 0.53 -9.91 4.65 0.70
2014-12-31 0.71 -8.60 4.94 0.80
2014-09-30 0.61 -7.71 4.75 0.90
2014-06-30 0.52 -6.83 4.57 1.00
2014-03-31 0.26 -6.38 4.23 0.95
2013-12-31 0.00 -5.93 3.90 0.90
2013-09-30 0.05 -5.83 3.84 0.96
2013-06-30 0.10 -5.74 3.77 1.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Factor Therapeutics made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Factor Therapeutics used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Factor Therapeutics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Factor Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Factor Therapeutics has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1TT Health

 How is Factor Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Factor Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Factor Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Factor Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Factor Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Factor Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Factor Therapeutics Company Filings, last reported 3 months ago.

DB:1TT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2.89 0.00 3.04
2019-09-30 2.89 0.00 3.04
2019-06-30 3.23 0.00 3.36
2019-03-31 3.23 0.00 3.36
2018-12-31 0.81 0.00 2.61
2018-09-30 0.81 0.00 2.61
2018-06-30 6.90 0.00 6.41
2018-03-31 6.90 0.00 6.41
2017-12-31 7.61 0.00 6.64
2017-06-30 10.31 0.00 7.02
2017-03-31 10.31 0.00 7.02
2016-12-31 14.43 0.00 12.67
2016-09-30 14.43 0.00 12.67
2016-06-30 15.52 0.00 14.38
2016-03-31 15.52 0.00 14.38
2015-12-31 3.77 0.00 2.74
2015-09-30 3.77 0.00 2.74
2015-06-30 13.33 0.00 5.58
2015-03-31 13.33 0.00 5.58
2014-12-31 11.96 0.00 2.81
2014-09-30 11.96 0.00 2.81
2014-06-30 16.86 0.00 7.08
2014-03-31 16.86 0.00 7.08
2013-12-31 20.22 0.00 10.32
2013-09-30 20.22 0.00 10.32
2013-06-30 13.97 0.00 4.86
  • Factor Therapeutics has no debt.
  • Factor Therapeutics has not taken on any debt in the past 5 years.
  • Factor Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • Factor Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Factor Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Factor Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1TT Dividends

 What is Factor Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Factor Therapeutics dividends.
If you bought €2,000 of Factor Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Factor Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Factor Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1TT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1TT Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Factor Therapeutics has not reported any payouts.
  • Unable to verify if Factor Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Factor Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Factor Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Factor Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Factor Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Factor Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1TT Management

 What is the CEO of Factor Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Factor Therapeutics has no CEO, or we have no data on them.
Management Team

Ros Wilson

TITLE
Consultant
COMPENSATION
A$401K
TENURE
1.3 yrs

Melanie Farris

TITLE
Company Secretary
TENURE
3.6 yrs
Board of Directors Tenure

Average tenure and age of the Factor Therapeutics board of directors in years:

3.7
Average Tenure
59
Average Age
  • The tenure for the Factor Therapeutics board of directors is about average.
Board of Directors

Cherrell Hirst

TITLE
Independent Chairman
COMPENSATION
A$26K
AGE
73
TENURE
5 yrs

John Michailidis

TITLE
Independent Non Executive Director
COMPENSATION
A$21K
TENURE
3.2 yrs

Keith Harding

TITLE
Member of Medical Advisory Board
TENURE
3.7 yrs

Ron Shannon

TITLE
Member of Medical Advisory Board

Chris Behrenbruch

TITLE
Independent Non Executive Director
COMPENSATION
A$22K
AGE
43
TENURE
4.5 yrs

Rob Kirsner

TITLE
Member of Medical Advisory Board
TENURE
3.7 yrs

David Margolis

TITLE
Member of Medical Advisory Board
TENURE
3.7 yrs

David Brookes

TITLE
Non-Executive Director
COMPENSATION
A$19K
AGE
59
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Nov 19 Sell Ansila Energy NL Company 08. Nov 19 08. Nov 19 -60,000,000 €0.00 €-130,408
01. May 19 Buy Ansila Energy NL Company 30. Apr 19 30. Apr 19 1,981,583 €0.00 €6,254
X
Management checks
We assess Factor Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Factor Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1TT News

Simply Wall St News

1TT Company Info

Description

Factor Therapeutics Limited operates as a clinical stage biotechnology company. The company was formerly known as Tissue Therapies Limited and changed its name to Factor Therapeutics Limited in May 2016. Factor Therapeutics Limited is based in Brisbane, Australia.

Details
Name: Factor Therapeutics Limited
1TT
Exchange: DB
Founded:
A$1,452,143
1,042,835,633
Website: http://www.factor-therapeutics.com
Address: Factor Therapeutics Limited
10 Eagle Street,
Level 21,
Brisbane,
Queensland, 4000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX FTT Ordinary Shares Australian Securities Exchange AU AUD 19. Mar 2004
DB 1TT Ordinary Shares Deutsche Boerse AG DE EUR 19. Mar 2004
CHIA FTT Ordinary Shares Chi-X Australia AU AUD 19. Mar 2004
Number of employees
Current staff
Staff numbers
0
Factor Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:53
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2017/08/14
Last earnings filing: 2020/02/19
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.